Help patients within the growing space of substance use disorders and mental health

Presentation Q3 Interim Report

NOVEMBER 4, 2020 - Listen to Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, presenting the latest development in Q3 2020 and prioritizes going forward.

The new future starts to take shape

NOVEMBER 4, 2020 - In Q3 the work to finalize a scalable platform to manage payment and reimbursement for DTx products was finalized. vorvida® och deprexis® were launched in the US and the first distribution agreements were signed. ZUBSOLV´s development was negatively impacted by increased competition at UHG/Humana and by Covid-19. Some strategic re-prioritisations were made to focus continued investments on key value drivers.

Lief Therapeutics winner of the Orexo/Lyfebulb Innovation Challenge

OCTOBER 15 2020 - The winner of the Orexo/Lyfebulb Innovation Challenge for substance use disorder (SUD) is announced. The well-renowned jury selected Rohan Dixit of Lief as the winner for his innovative wearable device that by measuring heart rate variability helps reduce anxiety, which is highly correlated to SUD.

Positive results from OX125 human PK study

JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.